ASCO Guidelines Strongly Recommend Apixaban for VTE in Cancer Cancer Network, 24 Jun 2023 “Apixaban is one of three direct inhibitors of factor Xa, but unlike rivaroxaban or edoxaban, it is administered twice daily.